This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Follow-up

Authoring team

  • the patient should be followed-up if the condition deteriorates despite lifestyle changes or drug treatment (1)
  • patient should be reviewed every 2-3 months
    • if treatment effective, it may be stopped
      • patient should be advised that their rosacea may relapse, and the same treatment may need to be started again. following options are available:
        • maintenance treatment:
          • continuous (e.g. a reduced dose of oral treatment for 2-6 months followed by a 'drug holiday')
          • intermittent (e.g. using a topical treatment on alternate days or twice a week)
          • 'stepping down' from oral to topical treatment
    • if treatment has been unsatisfactory:
      • for people receiving topical treatment, consider switching to an alternative topical treatment, or prescribing an oral antibiotic
      • for people receiving an oral antibiotic, consider adding a topical treatment, or seek specialist advice. An alternative oral antibiotic is unlikely to be of benefit
  • the aim of treatment is to suppress rosacea completely
  • once the rosacea has been successfully treated then treatment can be slowly withdrawn over several months - antibiotic treatment should not be suddenly stopped as this can cause a recurrence of the rosacea

Reference:

1. Rivero A. An update on the treatment of rosacea. Aust Prescr. 2018 Feb; 41(1): 20–24.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.